Insider Buying: Elanco Animal Health Incorporated (NYSE:ELAN) Director Acquires 10,000 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) Director Lawrence Erik Kurzius purchased 10,000 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Friday, March 7th, Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock. The stock was bought at an average price of $10.90 per share, for a total transaction of $109,000.00.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded up $0.16 during trading on Friday, reaching $10.47. The company's stock had a trading volume of 4,680,857 shares, compared to its average volume of 4,670,565. The stock has a 50-day moving average price of $11.49 and a two-hundred day moving average price of $12.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a one year low of $10.03 and a one year high of $18.80. The stock has a market capitalization of $5.18 billion, a P/E ratio of 26.16, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Remove Ads

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.08 earnings per share. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ELAN shares. Piper Sandler lowered their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Stifel Nicolaus lowered their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. UBS Group lowered their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Barclays decreased their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a "market perform" rating and a $14.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $15.17.

Institutional Trading of Elanco Animal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock worth $49,000 after buying an additional 2,044 shares during the period. Atria Investments Inc grew its position in shares of Elanco Animal Health by 57.9% during the 3rd quarter. Atria Investments Inc now owns 56,613 shares of the company's stock worth $832,000 after buying an additional 20,760 shares during the period. Venturi Wealth Management LLC grew its position in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock worth $50,000 after buying an additional 1,601 shares during the period. Versor Investments LP acquired a new position in shares of Elanco Animal Health during the 3rd quarter worth about $380,000. Finally, Rakuten Securities Inc. grew its position in shares of Elanco Animal Health by 270,525.0% during the 3rd quarter. Rakuten Securities Inc. now owns 10,825 shares of the company's stock worth $159,000 after buying an additional 10,821 shares during the period. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.